BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30982499)

  • 1. Nonsteroidal Anti-inflammatory Drugs Sensitize CD44-Overexpressing Cancer Cells to Hsp90 Inhibitor Through Autophagy Activation.
    Moon HJ; Park SY; Lee SH; Kang CD; Kim SH
    Oncol Res; 2019 Jul; 27(7):835-847. PubMed ID: 30982499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
    Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
    Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
    Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
    Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
    Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
    Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
    Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
    Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.
    Newman B; Liu Y; Lee HF; Sun D; Wang Y
    Cancer Res; 2012 Sep; 72(17):4551-61. PubMed ID: 22751135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition.
    Subramanian C; Grogan PT; Wang T; Bazzill J; Zuo A; White PT; Kalidindi A; Kuszynski D; Wang G; Blagg BSJ; Cohen MS
    Mol Oncol; 2020 Sep; 14(9):2058-2068. PubMed ID: 32255264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
    Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
    Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
    Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
    Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells.
    Wang B; Chen L; Ni Z; Dai X; Qin L; Wu Y; Li X; Xu L; Lian J; He F
    Exp Cell Res; 2014 Nov; 328(2):379-87. PubMed ID: 25196280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice.
    Yang R; Tang Q; Miao F; An Y; Li M; Han Y; Wang X; Wang J; Liu P; Chen R
    Int J Nanomedicine; 2015; 10():7345-58. PubMed ID: 26677324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.